Deferasirox (Exjade): A new iron chelator

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1233, 2006, Pages 35-36

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; AMINOTRANSFERASE; ANTACID AGENT; CREATININE; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; IRON CHELATING AGENT; BENZOIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CATARACT; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG COST; DRUG INDICATION; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEPATITIS; HUMAN; IRON OVERLOAD; NAUSEA; RASH; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; CONTROLLED CLINICAL TRIAL; DRUG MANUFACTURE; ECONOMICS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BENZOIC ACIDS; DRUG COSTS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; ORPHAN DRUG PRODUCTION; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 33646841819     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. GL Kontoghiorghes. New oral iron-chelating drugs for the treatment of transfusional iron overload and other diseases. Drugs Future 2005; 30:1241.
2. C Hershko. Treating iron overload: the state of the art. Semin Hematol 2005; 42 suppl 1:S2.
3. MD Cappellini et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator in patients with beta-thalassemia. Blood 2005; Dec 15:epub.
4. Based on most recent data (March 31, 2006) from retail pharmacies nationwide available from Wolters Kluwer Health.